The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Eli Lilly led a $100M equity round in Absci, investing $40M to advance ABS-201, the first AI-designed injectable antibody targeting hair loss and